Citi initiates Clovis Oncology at Buy, big upside seen


Finally, someone on the sell-side is out talking about Clovis Oncology (CLVS) which rallied sharply (then faded a bit) Tuesday on reports it's exploring a sale.

Citi has initiated the shares at Buy.

Price target is $109, representing 45% worth of upside from Thursday's close.

CLVS +2.6% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs